The outcomes of this study support the use of camrelizumab plus carboplatin and pemetrexed as first-line treatment options for Chinese patients with advanced non-squamous NSCLC without EGFR and ALK alterations. This evidence concerns the gene ALK and non-small cell lung carcinoma.